Drugmakers reported a string of positive late-stage oncology results, underscoring the growing role of combination therapies across tumor types. Johnson & Johnson said its dual-action tablet combining PARP inhibitor niraparib with androgen-signaling blocker abiraterone, plus prednisone and androgen-deprivation therapy, achieved a radiographic progression-free survival that was not yet reached in patients with homologous recombination repair–mutated metastatic hormone-sensitive prostate cancer, versus 29.5 months for the control arm in the Phase 3 AMPLITUDE study. The data support a July filing to extend the medicine’s European label. Bristol Myers Squibb’s checkpoint-inhibitor pairing ipilimumab and nivolumab prolonged progression-free survival compared with nivolumab alone in patients with microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancer, according to Phase 3 CheckMate 8HW results that also maintained health-related quality of life. In another colorectal cancer cohort limited to liver metastases, Hutchmed’s VEGFR inhibitor fruquintinib combined with best supportive care extended median overall survival to 8.5 months, more than doubling the 3.1 months seen with placebo. For liver cancer, adding Roche’s immunotherapy duo atezolizumab and bevacizumab to trans-arterial chemoembolization pushed investigator-assessed TACE progression-free survival to 11.3 months against 7.0 months with TACE alone in resectable hepatocellular carcinoma, meeting the study’s primary endpoint. Separately, AstraZeneca reported that incorporating PD-L1 inhibitor durvalumab into peri-operative FLOT chemotherapy produced no clinically meaningful deterioration in global health status, physical function or role function three months after treatment in patients with resectable gastric or gastro-esophageal junction cancer.